

The Flowr Corporation

14:35 30 Jul 2019

Flowr Corporation ships clones to fire up partner's cannabis operations in Aljustrel in Portugal

The Flowr Corporation (CVE:FLWR) (OTCQB:FLWPF) revealed Tuesday that it has received a Health Canada export permit allowing it to ship an initial batch of clones from its Kelowna Campus to Portugal to fire up its European partner, Holigen Holdings Limited's cannabis operation in Aljustrel .

Flowr operates large-scale, GMP-designed facilities that utilize proprietary growing methods to produce high-quality cannabis for recreational and medicinal use.

The Toronto-headquartered cannabis firm recently said it is raising C\$43.5 million via a bought deal financing agreement to acquire the about 80% equity interest in Holigen Holdings Limited that it does not already own.

READ: Flowr inks deal to acquire rest of Holigen

Holigen's subsidiary RPK Biopharma, Unipessoal Lda, has been greenlighted by Portugal's National Authority for Medicines and Health Products, or INFARMED to plant cannabis at its Aljustrel project in Portugal.

Flowr said it carried out an "intensive, nine-week" integrated pest management program to secure the phytosanitary certificates to ship the clones to Aljustrel. The company also has a clean stock protocol, which is a proprietary process to certify the company's cannabis clones are free of pests and pathogens.

Sending more shipments

Flowr noted that in the coming weeks it will deliver a "significantly larger" shipment of clones, which will position Aljustrel well for the planned 2019 planting and, ultimately, its first harvest later this year, pending final licensing.

Flowr CEO Vinay Tolia said: "INFARMED's authorization to plant cannabis at Aljustrel is a major milestone in the development of this project, a cornerstone of our effort to service the global medical cannabis market.

"Aljustrel is one of the largest outdoor THC cultivation licenses in the developed world, and will be instrumental in providing large-scale, low-cost cannabis extract for pharmaceutical APIs, as well as oils to service the European medical markets."

Tolia noted that the team at Holigen had advanced the project to this stage in "an efficient manner."

"This is a testament to their expertise in permitting and licensing. We look forward to bringing our cultivation expertise to this impressive opportunity, the first step of which constituted our successful initial shipment of healthy clones," he added.

Aljustrel is a rapidly developing site for cannabis production, extraction, and manufacturing facilities in Portugal. It has been designated a project of national interest by the Portuguese government, a designation that cuts down bureaucratic

Price: 1.81

Market Cap: \$193.63 m

1 Year Share Price Graph



Share Information

Code: FLWR

Listing: TSX-V

52 week	High	Low
	8.42	1.75

Sector: Cannabis

Website: flowr.ca

Company Synopsis:

The Flowr Corporation (TSXV: FLWR) (OTC: FLWPF), through its subsidiaries, holds a cannabis production and sales licence granted by Health Canada. With a head office in Toronto and a production facility in Kelowna, British Columbia, Flowr builds and operates large-scale, GMP-designed cultivation facilities utilizing its own patented growing systems.

action@proactiveinvestors.com

red tape, allows for quick regulatory licensing, as well as access to funding.

Working closely with Holigen

Holigen Holdings Ltd is a European cannabis company developing large-scale GMP-compliant grow facilities in Portugal and Australia. Flowr's strategic investment in Holigen provides the firm with the ability to dramatically increase global scale.

"Over the course of this year, we have worked closely with Holigen's management to help develop their incredible assets, notably Aljustrel, their Portuguese outdoor cultivation facility," said Flowr CEO Tolia.

Aljustrel, which is expected to be operational in the second half of 2019, is a planned seven-million-square-foot outdoor cultivation footprint with an expected ability to produce over 500,000 kilos annually.

Holigen is in the process of receiving all required licenses to operate the Aljustrel site in Portugal.

Flowr's flagship Kelowna production facility, currently under development, is expected to produce over 10,000 kilograms of premium flower annually once fully operational.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of The Flowr Corporation named herein, including the promotion by the Company of The Flowr Corporation in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).